Skip to main content
Premium Trial:

Request an Annual Quote

ViaLactia, Orion Pen Agricultural Genomics Deal

NEW YORK, May 31 – ViaLactia Biosciences of Auckland, New Zealand and Orion Genomics of St. Louis, Mo., said Thursday they had agreed to team up to develop improved species of forage plants as well as the technologies for agricultural genomics.

Under the terms of the deal, Orion will apply its GeneThresher technology to sequence and identify genes in important forage grass species.  The two companies will then work together to develop DNA microchips, SNP detection tools, and sequence databases.

Financial terms of the deal were not disclosed.

ViaLactia is hoping the alliance will help to boost the New Zealand economy.

“The pastoral industries in New Zealand contribute over 40 percent of the country’s export earnings,” said Kevin Marshall, managing director of ViaLactia Biosciences, a wholly owned subsidiary of the New Zealand Dairy Board. “Forage plant improvements will have an immediate and positive economic impact.”

Orion’s GeneThresher technology is designed to separate repetitive junk DNA from genes, allowing scientists to develop effective assays that can more readily hone in on gene function.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.